|
| | Publication Year | Title | Author(s) |
| 41 | Mar-2020 | Ceritinib plus Nivolumab in Patients with Advanced ALK-Rearranged Non-Small Cell Lung Cancer: Results of an Open-Label, Multicenter, Phase 1B Study. | Felip, Enriqueta; de Braud, Filippo G; Maur, Michela; Loong, Herbert H; Shaw, Alice Tsang; Vansteenkiste, Johan F; John, Thomas ; Liu, Geoffrey; Lolkema, Martijn P; Selvaggi, Giovanni; Giannone, Vanessa; Cazorla, Pilar; Baum, Jason; Balbin, O Alejandro; Wang, Luojun Victor; Lau, Yvonne Y; Scott, Jeffrey W; Tan, Daniel Shao-Weng |
| 42 | Feb-2020 | Entrectinib in patients with advanced or metastatic NTRK fusion-positive solid tumours: integrated analysis of three phase 1-2 trials. | Doebele, Robert C; Drilon, Alexander; Paz-Ares, Luis; Siena, Salvatore; Shaw, Alice T; Farago, Anna F; Blakely, Collin M; Seto, Takashi; Cho, Byung Chul; Tosi, Diego; Besse, Benjamin; Chawla, Sant P; Bazhenova, Lyudmila; Krauss, John C; Chae, Young Kwang; Barve, Minal; Garrido-Laguna, Ignacio; Liu, Stephen V; Conkling, Paul; John, Thomas ; Fakih, Marwan; Sigal, Darren; Loong, Herbert H; Buchschacher, Gary L; Garrido, Pilar; Nieva, Jorge; Steuer, Conor; Overbeck, Tobias R; Bowles, Daniel W; Fox, Elizabeth; Riehl, Todd; Chow-Maneval, Edna; Simmons, Brian; Cui, Na; Johnson, Ann; Eng, Susan; Wilson, Timothy R; Demetri, George D |
| 43 | Feb-2020 | Entrectinib in ROS1 fusion-positive non-small-cell lung cancer: integrated analysis of three phase 1-2 trials. | Drilon, Alexander; Siena, Salvatore; Dziadziuszko, Rafal; Barlesi, Fabrice; Krebs, Matthew G; Shaw, Alice T; de Braud, Filippo; Rolfo, Christian; Ahn, Myung-Ju; Wolf, Jürgen; Seto, Takashi; Cho, Byoung Chul; Patel, Manish R; Chiu, Chao-Hua; John, Thomas ; Goto, Koichi; Karapetis, Christos S; Arkenau, Hendrick-Tobias; Kim, Sang-We; Ohe, Yuichiro; Li, Yu-Chung; Chae, Young K; Chung, Christine H; Otterson, Gregory A; Murakami, Haruyasu; Lin, Chia-Chi; Tan, Daniel S W; Prenen, Hans; Riehl, Todd; Chow-Maneval, Edna; Simmons, Brian; Cui, Na; Johnson, Ann; Eng, Susan; Wilson, Timothy R; Doebele, Robert C |
| 44 | 22-Jan-2020 | A multicenter study of thromboembolic events among patients diagnosed with ROS1-rearranged non-small cell lung cancer. | Alexander, Marliese; Pavlakis, Nick; John, Thomas ; O'Connell, Rachel; Kao, Steven; Hughes, Brett G M; Lee, Adrian; Hayes, Sarah A; Howell, Viive M; Clarke, Stephen J; Millward, Michael; Burbury, Kate; Solomon, Benjamin; Itchins, Malinda |
| 45 | Jan-2020 | Programmed Cell Death Ligand 1 Expression in Untreated EGFR Mutated Advanced NSCLC and Response to Osimertinib Versus Comparator in FLAURA. | Brown, Helen; Vansteenkiste, Johan; Nakagawa, Kazuhiko; Cobo, Manuel; John, Thomas ; Barker, Craig; Kohlmann, Alexander; Todd, Alexander; Saggese, Matilde; Chmielecki, Juliann; Markovets, Aleksandra; Scott, Marietta; Ramalingam, Suresh S |
| 46 | Jan-2020 | Gefitinib and Pemetrexed Improve Survival in EGFR-Mutated NSCLC - Tarring all Patients With the Same Brush? | Arulananda, Surein; John, Thomas |
| 47 | 2020 | Overall Survival with Osimertinib in Untreated, EGFR-Mutated Advanced NSCLC. | Ramalingam, Suresh S; Vansteenkiste, Johan; Planchard, David; Cho, Byoung Chul; Gray, Jhanelle E; Ohe, Yuichiro; Zhou, Caicun; Reungwetwattana, Thanyanan; Cheng, Ying; Chewaskulyong, Busyamas; Shah, Riyaz; Cobo, Manuel; Lee, Ki Hyeong; Cheema, Parneet; Tiseo, Marcello; John, Thomas ; Lin, Meng-Chih; Imamura, Fumio; Kurata, Takayasu; Todd, Alexander; Hodge, Rachel; Saggese, Matilde; Rukazenkov, Yuri; Soria, Jean-Charles |
| 48 | Dec-2019 | Australian consensus statement for best practice ROS1 testing in advanced non-small cell lung cancer. | Pavlakis, Nick; Cooper, Caroline; John, Thomas ; Kao, Steven; Klebe, Sonja; Lee, Chee Khoon; Leong, Trishe Y-M; Millward, Michael; O'Byrne, Ken; Russell, Prudence A; Solomon, Benjamin; Cooper, Wendy A; Fox, Stephen |
| 49 | Dec-2019 | RET-rearranged non-small-cell lung cancer and therapeutic implications. | Loh, Zoe ; Mitchell, Paul L R ; John, Thomas ; Arulananda, Surein |
| 50 | 18-Oct-2019 | Ceritinib plus nivolumab in patients with advanced ALK-rearranged non-small-cell lung cancer: results of an open-label, multicenter, phase 1B study: Ceritinib plus nivolumab in ALK-rearranged NSCLC. | Felip, Enriqueta; de Braud, Filippo G; Maur, Michela; Loong, Herbert H; Shaw, Alice Tsang; Vansteenkiste, Johan F; John, Thomas ; Liu, Geoffrey; Lolkema, Martijn P; Selvaggi, Giovanni; Giannone, Vanessa; Cazorla, Pilar; Baum, Jason; Balbin, O Alejandro; Wang, Luojun Victor; Lau, Yvonne Y; Scott, Jeffrey W; Shao-Weng Tan, Daniel |
| 51 | 9-Oct-2019 | Brief Report: Programmed Cell Death Ligand 1 Expression in Untreated EGFR Mutated Advanced Non-Small Cell Lung Cancer and Response to Osimertinib versus Comparator in FLAURA. | Brown, Helen; Vansteenkiste, Johan; Nakagawa, Kazuhiko; Cobo, Manuel; John, Thomas ; Barker, Craig; Kohlmann, Alexander; Todd, Alexander; Saggese, Matilde; Chmielecki, Juliann; Markovets, Aleksandra; Scott, Marietta; Ramalingam, Suresh S |
| 52 | Sep-2019 | DDR Alterations as a Surrogate Marker for TMB in SCLC - Use it or Lose it? | Arulananda, Surein; Mitchell, Paul L R ; John, Thomas |
| 53 | May-2019 | Standard dose osimertinib for erlotinib refractory T790M-negative EGFR-mutant non-small cell lung cancer with leptomeningeal disease. | Arulananda, Surein; Do, Hongdo; Rivalland, Gareth; Loh, Zoe ; Musafer, Ashan; Lau, Eddie ; Mitchell, Paul; Dobrovic, Alexander ; John, Thomas |
| 54 | 24-Apr-2019 | BCL-XL and MCL-1 are the key BCL-2 family proteins in melanoma cell survival. | Lee, Erinna F; Harris, Tiffany J ; Tran, Sharon; Evangelista, Marco; Arulananda, Surein; John, Thomas ; Ramnac, Celeste; Hobbs, Chloe; Zhu, Haoran; Gunasingh, Gency; Segal, David; Behren, Andreas; Cebon, Jonathan S ; Dobrovic, Alexander ; Mariadason, John M ; Strasser, Andreas; Rohrbeck, Leona; Haass, Nikolas K; Herold, Marco J; Fairlie, W Douglas |
| 55 | 5-Apr-2019 | Combined tumor sequencing and case/control analyses of RAD51C in breast cancer. | Li, Na; McInerny, Simone; Zethoven, Magnus; Cheasley, Dane; Lim, Belle W X; Rowley, Simone M; Devereux, Lisa; Grewal, Norah; Ahmadloo, Somayeh; Byrne, David; Lee, Jue Er Amanda; Li, Jason; Fox, Stephen B; John, Thomas ; Antill, Yoland; Gorringe, Kylie L; James, Paul A; Campbell, Ian G |
| 56 | Apr-2019 | Entrectinib in NTRK fusion-positive non-small cell lung cancer (NSCLC): Integrated analysis of patients (pts) enrolled in STARTRK-2, STARTRK-1 and ALKA-372-001. | Paz-Ares, L; Doebele, R C; Farago, A F; Liu, S V; Chawla, S P; Tosi, D; Blakely, C M; Krauss, J C; Sigal, D; Bazhenova, L; John, Thomas ; Besse, B; Wolf, J; Seto, T; Chow-Maneval, E; Ye, C; Simmons, B; Demetri, G D |
| 57 | Apr-2019 | Mesenchyme to epithelial transition protein expression, gene copy number and clinical outcome in a large non-small cell lung cancer surgical cohort. | Rivalland, Gareth; Mitchell, Paul L R ; Murone, Carmel ; Asadi, Khashayer; Morey, Adrienne L; Starmans, Maud; Boutros, Paul C; Walkiewicz, Marzena; Solomon, Benjamin; Wright, Gavin; Knight, Simon; John, Thomas |
| 58 | Apr-2019 | Osimertinib as first-line (1L) treatment for epidermal growth factor receptor (EGFR) mutation-positive advanced non-small cell lung cancer (NSCLC): Final efficacy and safety results from two phase I expansion cohorts. | Yang, J C-H; Ramalingam, S S; Lee, C K; Kurata, T; Kim, D-W; John, Thomas ; Nogami, N; Ohe, Y; Rukazenkov, Y; Murphy, M; Jänne, P A |
| 59 | Apr-2019 | Entrectinib in locally advanced or metastatic ROS1 fusion-positive non-small cell lung cancer (NSCLC): Integrated analysis of ALKA-372-001, STARTRK-1 and STARTRK-2. | Barlesi, F; Drilon, A; De Braud, F; Cho, B C; Ahn, M J; Siena, S; Krebs, M G; Lin, C C; John, Thomas ; Tan, D S W; Seto, T; Dziadziuszko, R; Arkenau, H-T; Rolfo, C; Wolf, J; Ye, C; Riehl, T; Eng, S; Doebele, R C |
| 60 | 27-Mar-2019 | Epidermal growth factor receptor (EGFR)-targeted therapies in Mesothelioma. | Chia, Puey Ling ; Scott, Andrew M ; John, Thomas |
Loading...
2
0
20
0
false
0000-0003-3399-5342